# Phase II Study of Grass Pollen Allergy Vaccine BM32

> **NCT01538979** · PHASE2 · COMPLETED · sponsor: **Biomay AG** · enrollment: 181 (actual)

## Conditions studied

- Grass Pollen Allergy

## Interventions

- **BIOLOGICAL:** BM32
- **BIOLOGICAL:** BM32
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01538979
- **Lead sponsor:** Biomay AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2014-12
- **Final completion:** 2015-03
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2015-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01538979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01538979, "Phase II Study of Grass Pollen Allergy Vaccine BM32". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01538979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*